As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze

The market may be treating GLP-1 adoption as a broad snack-demand shock before the evidence supports that precision. Lower appetite can reduce category volume, but it does not map one-for-one to sales: consumers may trade toward smaller packs, higher-protein foods, or other occasions, while pricing and product mix can cushion units. The key read-through is therefore snack volume and mix—not headline grocery spending. Household-level studies also may not represent the marginal adopter or the full consumer base.

Over 1–3 months, the catalyst is quarterly disclosure: sustained weakness in snack volumes, unfavorable mix, or guidance changes would validate pressure on PepsiCo (PEP) and Hershey (HSY); stable volumes would challenge the rapid-disruption narrative. Coca-Cola (KO) may be relatively insulated by its portfolio mix, but it is not a clean hedge against all consumer substitution. Mondelēz (MDLZ) has a potential lagged exposure as adoption broadens outside the U.S.; emerging-market mix delays rather than eliminates that risk.

Over 6–18 months, drug makers benefit from broader access, but rising supply and competition can shift the debate from demand to net pricing, reimbursement, and capacity. Lilly (LLY) and Novo Nordisk (NVO) are not interchangeable: relative performance will depend on share, access, and execution, not simply category growth. Contrarian point: the food impact may be real but gradual, while current attribution of individual companies’ share moves to GLP-1s is not established by the article. Verify category-level shipment data and company guidance before sizing a structural short.